Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M24D1 in Gastrointestinal and Solid Tumors
NCT07279428Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BL-M24D1 in gastrointestinal tumor and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
BL-M24D1
03
Conditions
gastrointestinal tumorsolid tumor
Beyond the preview
Go deeper on NCT07279428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279428.